SSRIs, Pregnancy, and the Limits of the Obstetric Pen
When to start, when to refer, and why professional boundaries still matter. The Responsibility Clause — Ethical reasoning at the crossroads of autonomy, duty, and professionalism.
When Robert F. Kennedy Jr. publicly claimed in mid-2025 that antidepressant use in pregnancy causes autism, he wasn’t just spreading misinformation. He was undermining one of medicine’s most important principles: that risk must be measured, not imagined. His statements ignored decades of data and contradicted the consensus of ACOG and others—that the benefits of treating moderate to severe depression during pregnancy often outweigh the potential risks. The challenge is not choosing sides between fear and overconfidence. It’s learning how to balance them.
What SSRIs and SNRIs Actually Are
SSRIs (selective serotonin reuptake inhibitors) and SNRIs (serotonin–norepinephrine reuptake inhibitors) are the most studied psychiatric medications in pregnancy. Introduced in the 1980s with fluoxetine (Prozac), these agents increase neurotransmitters that regulate mood. Common SSRIs include fluoxetine, sertraline, citalopram, escitalopram, and paroxetine. SNRIs like venlafaxine and duloxetine affect both serotonin and norepinephrine.
Over 30 years of research, including large registry studies from the U.S., Denmark, and the U.K., have shown that most SSRIs are not linked to major congenital malformations. Some small associations—like paroxetine and certain cardiac defects—exist, but absolute risks remain low. The most common neonatal effect, transient adaptation syndrome, resolves spontaneously within days. These findings have placed SSRIs among the most evidence-supported medications used in pregnancy.
But data are not the whole story. The question is not only whether SSRIs are “safe,” but whether ObGyns should be the ones to initiate them.
The Evidence and the Risks
Untreated maternal depression and anxiety carry well-established dangers: increased risk of suicide, preterm birth, preeclampsia, low birth weight, and postpartum depression. Yet medications also have potential downsides—neonatal adaptation symptoms in about 25–30% of late-exposed infants, a very small possible association with persistent pulmonary hypertension, and a modestly higher cardiac-defect risk with paroxetine.
ACOG’s 2023 guideline emphasizes balance:
“The use of SSRIs or SNRIs during pregnancy should be individualized, weighing the benefits of treatment for the mother against potential risks for the fetus. Untreated maternal depression carries significant risk to both.”
That is not a license to prescribe freely. It is a reminder to evaluate deliberately.
When Obstetricians May Consider Initiating SSRIs
In some cases, obstetricians may appropriately initiate SSRI treatment for mild to moderate depression or anxiety, particularly when psychiatric access is limited. However, this decision should always involve collaboration with a mental health specialist and shared decision-making with the patient.
Factors supporting obstetrician-initiated SSRI treatment:
Frontline access: OB-GYNs are often the first—and sometimes the only—healthcare providers to screen pregnant women for depression or anxiety. Early treatment can prevent worsening illness.
Established standard of care: ACOG supports the role of ObGyns in initiating treatment when needed, provided systems exist for referral and follow-up.
Continuity of stable therapy: If a woman is already well controlled on an SSRI before pregnancy, continuing the same medication is usually preferred over switching or stopping.
Safety profile: Most SSRIs, especially sertraline, have reassuring safety data when used appropriately.
Even so, “can” does not always mean “should.” Obstetricians occupy a crucial but limited role: we recognize illness, initiate temporary care if necessary, and connect patients to psychiatric management for ongoing treatment.
When to Refer to a Mental Health Specialist
Referral or co-management with a psychiatrist or psychologist is strongly advised in these situations:
Severe or complex illness: Major depressive episodes with suicidality, bipolar disorder, psychosis, or OCD.
Lack of response: Failure to improve after an adequate trial or presence of side effects requiring dose adjustments or medication changes.
Need for psychotherapy: Cognitive behavioral or interpersonal therapy is first-line for many mild and moderate cases and should complement pharmacologic care.
Diagnostic uncertainty: Overlapping or unclear psychiatric presentations.
Consultation model: In collaborative care, the ObGyn serves as the primary contact while a psychiatrist provides oversight and treatment guidance.
This model keeps obstetricians within professional scope while ensuring patients receive expert mental health care.
Why Boundaries Matter
Starting an SSRI seems simple: write a prescription and follow up. But that simplicity is deceptive. Psychiatric diagnosis requires nuance—distinguishing major depression from bipolar disorder, anxiety from trauma, despair from adjustment. Missteps can cause harm, including medication-induced mania or undertreatment of serious psychiatric disease.
Obstetricians receive limited psychiatric training. We manage hypertension, diabetes, and hemorrhage expertly, but not complex psychopharmacology.
Professionalism means knowing when our reach should stop. Continuing a patient’s pre-existing SSRI? Yes. Managing her therapy in consultation with a psychiatrist? Appropriate. But initiating long-term antidepressant therapy without collaboration crosses a professional boundary.
Weighing Risks and Benefits
Every decision must be individualized:
Risks of untreated depression:
Suicide and self-harm
Preterm birth and low birth weight
Preeclampsia
Impaired bonding and increased postpartum depression
Potential risks of SSRI use:
Neonatal adaptation syndrome (NAS): 25–30% of late-exposed infants, mild and transient
Persistent pulmonary hypertension (PPHN): Rare, <1%, likely multifactorial
Paroxetine: Slightly higher risk of cardiac defects; sertraline preferred
The risk-benefit discussion should be explicit, documented, and revisited as pregnancy progresses.
The Ethical Core
The debate about SSRIs is ultimately a debate about trust. Patients trust us to tell them the truth, not to minimize risk or exaggerate it. Kennedy’s falsehoods exploit public fear; uncritical prescribing exploits clinical shortcuts. Both betray that trust.
Ethical practice lies between the two extremes: recognize illness early, provide accurate information, initiate only when appropriate, and partner with psychiatry whenever possible.
Reflection / Closing:
Obstetricians should remain the first eyes, not the final hands, in managing perinatal mental illness. The pen that writes the prescription carries both power and responsibility. Using it wisely means knowing when to put it down—and when to call for help.